MX2015008830A - Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central. - Google Patents
Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central.Info
- Publication number
- MX2015008830A MX2015008830A MX2015008830A MX2015008830A MX2015008830A MX 2015008830 A MX2015008830 A MX 2015008830A MX 2015008830 A MX2015008830 A MX 2015008830A MX 2015008830 A MX2015008830 A MX 2015008830A MX 2015008830 A MX2015008830 A MX 2015008830A
- Authority
- MX
- Mexico
- Prior art keywords
- halogen
- lower alkyl
- treatment
- alkyl substituted
- phenyl
- Prior art date
Links
- 102000004279 Oxytocin receptors Human genes 0.000 title 1
- 108090000876 Oxytocin receptors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/42—Benzene-sulfonamido pyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13151632 | 2013-01-17 | ||
| PCT/EP2014/050526 WO2014111356A1 (en) | 2013-01-17 | 2014-01-14 | Oxytocin receptor agonists for the treatment of cns diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015008830A true MX2015008830A (es) | 2015-10-14 |
Family
ID=47559324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008830A MX2015008830A (es) | 2013-01-17 | 2014-01-14 | Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9751870B2 (enExample) |
| EP (1) | EP2945624B1 (enExample) |
| JP (1) | JP6263553B2 (enExample) |
| KR (1) | KR20150108384A (enExample) |
| CN (1) | CN104936593B (enExample) |
| BR (1) | BR112015016323A2 (enExample) |
| CA (1) | CA2898015A1 (enExample) |
| MX (1) | MX2015008830A (enExample) |
| RU (1) | RU2664705C2 (enExample) |
| WO (1) | WO2014111356A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| US10441627B2 (en) * | 2014-09-19 | 2019-10-15 | Ferring B.V. | Method of treating prader-willi syndrome |
| EP3852723B1 (en) | 2018-09-20 | 2025-11-05 | ACADIA Pharmaceuticals Inc. | Stable intranasal formulations of carbetocin |
| AU2019345313A1 (en) | 2018-09-20 | 2021-03-18 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| WO2020178441A1 (en) * | 2019-03-06 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of ngal protein |
| WO2022200568A1 (en) | 2021-03-26 | 2022-09-29 | Ot4B | Treatment of dysphagia |
| CN116459261A (zh) * | 2023-02-27 | 2023-07-21 | 徐州医科大学 | Lit-001在治疗焦虑疾病中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3014038A (en) | 1961-12-19 | Xnhxs | ||
| DE1115739B (de) | 1958-06-25 | 1961-10-26 | Ciba Geigy | Verfahren zur Herstellung von 1-Phenyl-5-(benzolsulfonamido)-pyrazolen |
| GB893755A (en) | 1958-06-25 | 1962-04-11 | Ciba Ltd | New pyrazoles and process for their manufacture |
| GB865341A (en) | 1958-07-30 | 1961-04-12 | Bayer Ag | 5-benzene-sulphonamido-1-phenyl pyrazole derivatives |
| DE1115261B (de) | 1958-07-30 | 1961-10-19 | Bayer Ag | Verfahren zur Herstellung von 1-Phenyl-5-(benzolsulfonamido)-pyrazolen |
| FR3797M (fr) * | 1963-11-05 | 1965-12-27 | Ciba Geigy | Nouvelle préparation pharmaceutique pour le traitement du diabetes mellitus. |
| US6531478B2 (en) * | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| FR2864958B1 (fr) * | 2004-01-12 | 2006-02-24 | Sanofi Synthelabo | Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique. |
| AU2008321823B2 (en) * | 2007-11-13 | 2013-03-07 | Taisho Pharmaceutical Co., Ltd. | Phenylpyrazole derivatives |
| EP2417123A2 (en) | 2009-04-06 | 2012-02-15 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| WO2012016229A2 (en) | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
-
2014
- 2014-01-14 JP JP2015553055A patent/JP6263553B2/ja not_active Expired - Fee Related
- 2014-01-14 RU RU2015130950A patent/RU2664705C2/ru not_active IP Right Cessation
- 2014-01-14 BR BR112015016323A patent/BR112015016323A2/pt not_active Application Discontinuation
- 2014-01-14 KR KR1020157021897A patent/KR20150108384A/ko not_active Withdrawn
- 2014-01-14 CA CA2898015A patent/CA2898015A1/en not_active Abandoned
- 2014-01-14 MX MX2015008830A patent/MX2015008830A/es unknown
- 2014-01-14 CN CN201480004903.5A patent/CN104936593B/zh not_active Expired - Fee Related
- 2014-01-14 EP EP14700614.2A patent/EP2945624B1/en not_active Not-in-force
- 2014-01-14 WO PCT/EP2014/050526 patent/WO2014111356A1/en not_active Ceased
-
2015
- 2015-07-17 US US14/802,469 patent/US9751870B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016506910A (ja) | 2016-03-07 |
| CN104936593B (zh) | 2018-05-18 |
| US20150322058A1 (en) | 2015-11-12 |
| KR20150108384A (ko) | 2015-09-25 |
| EP2945624A1 (en) | 2015-11-25 |
| RU2015130950A (ru) | 2017-02-21 |
| JP6263553B2 (ja) | 2018-01-17 |
| EP2945624B1 (en) | 2018-04-18 |
| CA2898015A1 (en) | 2014-07-24 |
| RU2664705C2 (ru) | 2018-08-21 |
| CN104936593A (zh) | 2015-09-23 |
| US9751870B2 (en) | 2017-09-05 |
| HK1209032A1 (en) | 2016-03-24 |
| BR112015016323A2 (pt) | 2017-07-11 |
| WO2014111356A1 (en) | 2014-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015008830A (es) | Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central. | |
| NZ708175A (en) | Peptides as oxytocin agonists | |
| PH12016502251A1 (en) | Peptides as oxytocin agonists | |
| MX2015017491A (es) | Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona. | |
| EA201692558A1 (ru) | Производные индолин-2-она или пирролопиридин-2-она | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| CO2017011174A2 (es) | Derivados de etileno como moduladores metabotropicos de receptores de glutamato | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| MX2016007056A (es) | Metodos para preparar compuestos de benzoquinolina. | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| PH12016500427A1 (en) | Ethynyl derivatives | |
| AR083595A1 (es) | Derivados de indol y el proceso para su preparacion | |
| PH12016502232A1 (en) | Peptides as oxytocin agonists | |
| PE20150685A1 (es) | Pirimidinas de ariletinilo | |
| MX374574B (es) | Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona. | |
| TH171910A (th) | เปบไทด์ที่เป็นออกซีโทซินอะโกนิสต์ | |
| AR075183A1 (es) | Compuestos de 2-aza-biciclo (2,2,1) heptano y sus usos | |
| ECSP12012356A (es) | Derivados de quinolizidina e indolizidina |